文献速递流行病学与生物统计临床试验与 GCP基础与转化研究

利用自然史数据提升SCA2试验统计效能的方法研究

How to improve statistical power in a trial with SCA2 patients using natural history data.
PubMed 文献 · Trials · 2026-03-05

针对罕见神经退行性疾病SCA2的随机对照试验样本量受限问题,本研究利用疾病进程映射构建自然史进展模型,并将预测效能推断(PPCT)、预后协变量调整和H-AIPW三种方法应用于ATRIL试验。结果显示三种方法均降低治疗效应估计方差,PPCT可减少14.5%样本量(6例患者),且不改变原试验结论。

要点

  • PPCT、预后协变量调整和H-AIPW均降低治疗效应估计方差,提升统计效能。
  • PPCT方法可减少14.5%(6例)样本量,对罕见病试验意义重大。
  • 利用自然史数据的外部信息可缩短置信区间,但不改变ATRIL试验结论。

核心结论

  • 应用PPCT、预后协变量调整或H-AIPW方法可利用外部自然史数据降低方差、提升统计效能或减少所需样本量。
  • ATRIL试验关于利鲁唑的结论未改变,但上述方法本可允许选择更少患者。

研究设计与样本

  • 方法学研究,将疾病进程映射训练的自然史进展模型应用于ATRIL随机双盲安慰剂对照试验的SCA2患者数据。
  • 自然史模型训练数据来自美国和欧洲队列(EUROSCA、SPATAX、CRC-SCA)。
  • 比较PPCT、预后协变量调整和H-AIPW三种方法与经典方差估计的效能。

主要发现

  • 疾病进程映射模型预测的一年SARA评分进展与观测值的相关性约为0.15。
  • 治疗效应估计方差:PPCT为0.342,预后协变量调整0.344,H-AIPW为0.348,经典方差为0.407。
  • PPCT可减少样本量14.5%(6例患者),即用39例而非45例可达到ATRIL论文报告的相同方差。

临床怎么用

  • 在罕见神经退行性疾病试验设计中,可考虑采用PPCT、预后协变量调整或H-AIPW方法利用自然史数据提升效能。
  • 上述方法有助于减少所需样本量,但需确保自然史数据与试验人群的可比性。

局限性

  • 自然史模型预测的一年SARA评分进展与观测值的相关性仅约0.15,预测准确性有限。
  • 研究仅针对SCA2和ATRIL试验,结论外推至其他疾病或试验需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomized, double-blind, placebo-controlled trials are the gold standard for evaluating treatment effects, as they minimize biases. However, they raise ethical concerns regarding participant exposure to potentially ineffective interventions. For rare neurodegenerative diseases, these trials are further challenged by the limited number of patients. Our goal is to leverage recent advancements in statistical methodologies to enhance the statistical power of these trials. We aim to test these methods to the ATRIL study, which evaluated the efficacy of riluzole in patients with dominant cerebellar ataxia SCA2. We trained a progression model on natural history data to capture the progression of the disease, using Disease Course Mapping. We explored the prediction-powered inference for clinical trials method (PPCT), which leverages the prognostic scores predicted by this model, to offer an unbiased comparison between the observed progression in treated patients and the predicted progression if they had not been treated. Then, we compared PPCT to the prognostic covariate adjustment and the Hybrid Augmented Inverse Probability Weighting (H-AIPW) methods, which respectively incorporate the prognostic score to the analysis of covariance or to the Augmented Inverse Probability Weighting (AIPW) method. These methods were applied to the ATRIL trial, which included treated and placebo SCA2 patients, using a model trained on patients from US and European cohorts (EUROSCA, SPATAX, CRC-SCA). Disease Course Mapping models accurately forecasted the prognostic scores, namely the predicted one-year SARA score progression, with correlations around 0.15. The treatment effect estimator had a lower variance using the PPCT (0.342), prognostic covariate adjustment (0.344), and H-AIPW (0.348) methods compared to the classical variance (0.407). Notably, PPCT would reduce the sample size by 14.5% (6 patients). Using the PPCT estimator of the average treatment effect, the same variance reported in the ATRIL paper could have been achieved with 39 patients instead of 45. Our study addresses the challenge of statistical power in clinical trials and explores new methodological advancements. Applying the PPCT, prognostic covariate adjustment, or H-AIPW methods helps reduce confidence intervals, enhance statistical power, or decrease the required sample size for the trial by leveraging information from external data. Although the ATRIL's trial conclusion on riluzole remains unchanged, these methods could have enabled the selection of fewer patients, which is crucial for rare neurodegenerative diseases.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tran M, Poulet PE, Petit E, et al. How to improve statistical power in a trial with SCA2 patients using natural history data. Trials. 2026. PMID: 41787540. doi:10.1186/s13063-026-09591-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。